Commentary

Article

State of the Science Summit - Hematologic Malignancies: Chaired by Rebecca Klisovic, MD

State of the Science Summit - Hematologic Malignancies: Chaired by Rebecca Klisovic, MD

State of the Science Summit - Hematologic Malignancies: Chaired by Rebecca Klisovic, MD

Speakers

  • Molly Gallogly, MD, PhD | University Hospitals Seidman Cancer Center
  • Leland Metheny, MD | University Hospitals Seidman Cancer Center
  • Benjamin Tomlinson, MD | University Hospitals Seidman Cancer Center
  • Changchun Deng, MD, PhD | University Hospitals Seidman Cancer Center
  • James Ignatz-Hoover, MD | University Hospitals Seidman Cancer Center

Topics

  • Panel Discussion & Case Presentation: Which JAK Inhibitor for MF?
  • Updates in MDS and AML
  • Treatment Crossroads: Sequencing BTK Inhibitors in CLL
  • A New Era: Bispecifics for Hematologic Malignancies
  • Exciting Studies to Look for in 2024 in Hematologic Malignancies

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
Justin M. Watts, MD
Mazyar Shadman, MD, MPH
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study